Book your liver cancer consult

What is liver cancer

Liver cancer means a tumour that begins in the cells of the liver itself, not one that has spread to the liver from somewhere else. The vast majority of these tumours are hepatocellular carcinoma, which arises from hepatocytes, the liver’s main working cells. A smaller share are cholangiocarcinomas, which start in the bile-duct lining inside the liver. Children sometimes develop hepatoblastoma, a different disease. When people say liver cancer in clinic, they almost always mean hepatocellular carcinoma, abbreviated HCC [3][5].

The liver sits under the right side of the rib cage. It filters blood, makes bile for digestion, stores sugar, and breaks down drugs. HCC tends to grow inside a liver that is already scarred from long-standing damage. Hepatitis B virus, hepatitis C virus, heavy alcohol use, and fatty liver disease are the usual causes of that scarring. Once scarring becomes cirrhosis, the risk of HCC each year is small but real, and it adds up over many years [4][9][10]. Cancer cells can spread along blood vessels inside the liver, into the portal vein, into nearby lymph nodes, or further out to lung and bone.

In India, the picture is sobering. Globocan 2022 places liver cancer among the leading causes of cancer death in Indian men, with new cases counted in the tens of thousands each year and a death toll close to the case count, because most tumours are found late [1][6]. Awareness in north Indian outpatient clinics is low until jaundice or pain has already arrived.

Main subtypes of liver cancer

Hepatocellular carcinoma (HCC) is the dominant form, making up the large majority of primary liver cancers in adults [3]. Within HCC, pathologists describe growth patterns (trabecular, pseudoglandular, solid, scirrhous) and grades from well differentiated to poorly differentiated. Fibrolamellar HCC is a rare variant seen in younger patients without underlying cirrhosis; it behaves differently and is sometimes resectable when classical HCC would not be.

Intrahepatic cholangiocarcinoma starts in the bile-duct lining and is usually an adenocarcinoma. It is treated more like a biliary tract cancer than like HCC, and the staging and chemotherapy choices differ. Combined hepatocellular-cholangiocarcinoma is a less common hybrid tumour. Hepatoblastoma is a paediatric tumour with its own protocols.

A few molecular features matter for treatment choice. Tumours can be checked for PD-L1, microsatellite instability, and, in cholangiocarcinoma, for FGFR2 fusions, IDH1 mutations, BRAF V600E, and HER2 overexpression. These checks open up targeted-therapy options that did not exist a few years ago [4].

Early signs and symptoms of liver cancer

Early HCC often has no symptoms at all. When signs appear, they tend to come from a tumour that is already large or from cirrhosis getting worse. Patients should not wait for several of these to appear before asking for a scan.

• A dull ache or heaviness in the upper-right abdomen, sometimes spreading to the right shoulder. The liver capsule is being stretched.
• A hard lump felt under the right ribs — the tumour itself or an enlarged liver.
• Yellowing of the eyes and skin (jaundice). Bile is backing up because the tumour is blocking ducts or the liver is failing.
• Swelling of the abdomen with fluid (ascites). Portal vein pressure is rising.
• Loss of appetite and feeling full after a few mouthfuls.
• Unintended weight loss over weeks to months, often with muscle wasting in the temples and shoulders.
• Dark urine and pale stools, classic signs that bile is not reaching the gut.
• Easy bruising, gum bleeding, or a nosebleed that will not stop. The liver makes clotting factors, and it has stopped doing that job properly.
• Itching all over the body, usually worse at night, from bile salts in the skin.
• Fever without an obvious infection.
• Confusion, drowsiness, or a tremor of the outstretched hands — hepatic encephalopathy, a sign that liver failure is advanced.
• A new variceal bleed, vomiting bright red blood, in someone known to have hepatitis or cirrhosis.

Causes and Indian-population risk factors

Almost every case of HCC has a back-story. The liver does not turn cancerous in a healthy organ very often [4][5]. The main drivers in India are well known and largely preventable.

Chronic hepatitis B is the single biggest cause in India and across most of Asia [9]. The virus integrates into hepatocyte DNA and drives cancer even in livers that are not yet cirrhotic. Vertical transmission from mother to child remains common in pockets of north and east India.

Chronic hepatitis C is the second large viral driver, more often acquired through unsafe injections, unscreened transfusions before the late 1990s, and contaminated dental or surgical instruments [10]. Direct-acting antiviral cures now exist, but a person who clears the virus after cirrhosis has set in still carries lifetime HCC risk and needs ongoing surveillance.

Alcohol-related cirrhosis is rising fast in Indian men, especially in Punjab, Kerala, and the north-east. Daily heavy drinking over a decade or more is the usual pattern. Alcohol multiplies the risk in anyone who also has HBV, HCV, or fatty liver.

Non-alcoholic fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease, is the fastest-growing cause of HCC in urban India. Type 2 diabetes, central obesity, and metabolic syndrome are the inputs. HCC can develop in a fatty liver before full cirrhosis is present.

Aflatoxin exposure is an under-recognised driver in parts of India where groundnut, maize, and chilli storage is humid. Aspergillus moulds produce aflatoxin B1, classified by IARC as a Group 1 human carcinogen [11]. The combination of aflatoxin and HBV multiplies risk many times over.

Inherited and metabolic disorders account for a smaller share. Hereditary haemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen storage diseases, and tyrosinaemia all raise risk.

Tobacco use, both smoking and chewing, is an independent risk factor for HCC in Indian cohorts. The age curve in Indian patients runs younger than in western series — many men present in their fifties, a decade earlier than SEER cohorts [3][6].

How we diagnose liver cancer at HealOnco

The diagnosis of HCC is unusual in oncology because, in the right clinical setting, imaging alone can be enough to confirm it without a biopsy.

Surveillance. A patient with risk factors, most often known cirrhosis or chronic HBV, should be in a surveillance programme — ultrasound of the liver every six months, with or without serum alpha-fetoprotein (AFP) [4][5]. Most tumours found on surveillance are small and treatable.

Multiphase imaging and LI-RADS. When ultrasound flags a nodule, the next test is a multiphase contrast-enhanced CT or MRI. The radiologist looks for the classical signature of HCC: arterial-phase hyperenhancement, washout in the portal venous or delayed phase, and a capsule. The Liver Imaging Reporting and Data System (LI-RADS) gives a standard way to score these features. A LI-RADS 5 lesion in a cirrhotic liver is treated as HCC without a biopsy.

Tumour markers. Serum AFP is measured but is no longer used in isolation. Many small HCCs do not raise AFP. AFP-L3 and DCP (PIVKA-II) are extra markers used in some Indian centres.

Biopsy. A liver biopsy is taken when imaging is not classical, when the liver is not cirrhotic, or when systemic therapy decisions need a tissue diagnosis with molecular testing.

Staging work-up. CT chest for lung metastases, bone scan if pain suggests it, MRI brain occasionally. Liver function is graded by the Child-Pugh score and the more modern ALBI grade. Performance status is recorded with the ECOG scale. Endoscopy looks for varices that may need banding before any procedure. For cholangiocarcinoma, MRCP maps the bile ducts, CA 19-9 is measured, and molecular profiling screens for FGFR2 fusions, IDH1, BRAF V600E, HER2, and microsatellite instability [4].

Stages of liver cancer (TNM 8e and BCLC)

HCC is staged in two ways at the same time, and both numbers matter.

TNM 8th edition (AJCC/UICC)

Stage	Definition
T1a	Solitary tumour up to 2 cm
T1b	Solitary tumour larger than 2 cm without vascular invasion
T2	Solitary tumour larger than 2 cm with vascular invasion, or multiple tumours all 5 cm or smaller
T3	Multiple tumours with at least one larger than 5 cm
T4	Tumour invading a major branch of portal/hepatic vein, or invading nearby organs other than gallbladder, or perforating peritoneum
N1	Regional lymph nodes involved
M1	Distant metastases
Stage IA	T1aN0M0
Stage IB	T1bN0M0
Stage II	T2N0M0
Stage IIIA	T3N0M0
Stage IIIB	T4N0M0
Stage IVA	Any T, N1, M0
Stage IVB	Any T, any N, M1

Barcelona Clinic Liver Cancer (BCLC) system

Oncologists actually use BCLC to choose treatment because it folds in liver function and performance status. BCLC 0 (very early) — single tumour up to 2 cm, preserved liver function, no symptoms; cure is possible. BCLC A (early) — single tumour or up to three tumours each 3 cm or smaller, preserved function, no symptoms; curative treatment is offered. BCLC B (intermediate) — multifocal disease without vascular invasion or spread; locoregional therapy is the mainstay. BCLC C (advanced) — portal vein invasion or distant spread, or symptomatic disease; systemic therapy is offered. BCLC D (terminal) — poor liver function and poor performance status; the focus is comfort. Survival depends overwhelmingly on BCLC stage at diagnosis [3][6]. For intrahepatic cholangiocarcinoma, AJCC has its own TNM table and prognosis is generally worse than HCC of similar T stage.

Treatment options for liver cancer

Treatment for liver cancer is more individual than for almost any other tumour, because the doctor is treating two diseases at once: the cancer and the diseased liver underneath it. Decisions are made in a multidisciplinary tumour board with a hepatobiliary surgeon, an interventional radiologist, a medical oncologist, a radiation oncologist, and a hepatologist.

Surgical resection

What it is. Removal of the segment or lobe containing the tumour, leaving enough functioning liver behind. How it is done at HealOnco. Open or laparoscopic approach with intraoperative ultrasound, CUSA dissector, and low central venous pressure anaesthesia to reduce blood loss. Best for. Solitary HCC in a liver that still works well, with no portal hypertension and no vascular invasion. Benefits vs older techniques. Modern hepatobiliary units publish five-year survival in the high range for clean resections of single small HCCs (TMC, AIIMS series) [7][8]. Side effects. Bleeding, bile leak, transient liver dysfunction, infection. Honest assessment. Recurrence in the rest of the liver remains the main problem.

Liver transplantation

What it is. Removes the cancer and the diseased liver in one operation. How. Selection by Milan criteria (single tumour up to 5 cm, or up to three tumours each 3 cm or smaller, no vascular invasion or spread) or expanded Indian-programme criteria. Honest assessment. Long waiting list, donor scarcity, lifelong immunosuppression. Bridging therapy is often needed while waiting.

Local ablation (RFA, microwave, ethanol)

What it is. A needle placed under image guidance heats the tumour to a temperature that kills cancer cells. Best for. Very early HCC up to 3 cm; results approach surgery in many published series.

TACE — transarterial chemoembolisation

What it is. An interventional radiologist threads a catheter into the artery feeding the tumour and delivers doxorubicin-eluting microspheres followed by an embolic agent. Best for. Intermediate-stage (BCLC B) HCC. Can keep disease under control for years in selected patients. Honest assessment. Not safe with portal vein thrombosis.

Y-90 radioembolisation (TARE)

What it is. Yttrium-90 microspheres deliver internal radiation directly to the tumour through the same arterial route. Best for. Patients with portal vein thrombosis or those who have outgrown TACE.

Stereotactic body radiotherapy (SBRT)

What it is. A high, focused dose of external radiation delivered in a small number of sessions. Best for. Tumours that cannot be reached by ablation or surgery and patients waiting for a transplant.

Systemic therapy — first line and beyond

Atezolizumab plus bevacizumab is the first-line standard for advanced HCC with preserved liver function. The IMbrave150 trial showed an overall survival benefit over sorafenib [4]. Durvalumab plus tremelimumab (STRIDE) from HIMALAYA is another first-line immunotherapy doublet. TKIs used first or second line: sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab (in patients with high AFP). Choice depends on liver function, varices, bleeding risk, and what the patient can afford.

For intrahepatic cholangiocarcinoma, the chemotherapy backbone is gemcitabine plus cisplatin, often combined with durvalumab after the TOPAZ-1 trial. Targeted options include pemigatinib and infigratinib for FGFR2 fusion-positive disease, ivosidenib for IDH1-mutant disease, and HER2-directed therapy in HER2-amplified tumours [4].

Why bridging and downstaging matter

Sequencing matters in HCC because the liver will only forgive so much. A surgeon will not operate if the future liver remnant is too small or too sick. An interventional radiologist will not do TACE if the portal vein is blocked. A medical oncologist will not start atezolizumab plus bevacizumab in a patient with untreated varices, because the bleeding risk is too high. Bridging therapy with TACE, RFA, or SBRT keeps the tumour controlled while a transplant list is waiting; downstaging with the same tools can bring a borderline tumour back inside Milan criteria. That is why a tumour board, not a single doctor, decides.

A day at HealOnco — what to expect

Your first visit starts at the front desk with a single registration. You meet a hepatobiliary co-ordinator who takes your history, your earlier scans on a USB, and your blood reports. Within the same visit you see a medical oncologist and, if needed, a hepatologist. If imaging is needed we book a same-day or next-day multiphase CT or MRI. Blood is drawn in the daycare for AFP, LFTs, INR, viral serology, and a complete blood count. Your case is discussed at the next hepatobiliary tumour board, usually within 48 hours. You leave with a written plan, a written cost estimate, and a phone number that reaches a human, not a switchboard. Treatment day for TACE or ablation is a planned admission with overnight observation in most cases. Systemic therapy runs in our daycare with a recliner, a nurse who knows your name, and a pharmacist who checks every dose against your latest LFTs.

Liver cancer treatment cost in India

Cost in liver cancer is harder to quote than in most cancers, because the treatment plan changes so much from patient to patient. The figures below are typical ranges in private daycare and tertiary settings in north India.

Scenario	Treatment	Typical ₹ range
Very early HCC, single 2 cm nodule	RFA or microwave ablation	₹1.5–3 L
Early HCC, single resectable tumour	Open or laparoscopic liver resection	₹4–10 L
Living-donor liver transplant within criteria	Work-up, surgery, ICU, year-1 immunosuppression	₹25–45 L
Intermediate HCC, multifocal	TACE, 2–4 sessions	₹1–2 L per session
Advanced HCC, BCLC C	Atezolizumab + bevacizumab	₹2–3 L per cycle (q3w)
Advanced HCC, oral TKI	Lenvatinib or sorafenib	₹15,000–60,000 per month
Advanced cholangiocarcinoma	Gem + cis + durvalumab	₹1.5–2.5 L per cycle

These ranges leave out hospital stay, blood products, scans, and the cost of treating cirrhosis complications, which can be significant. Insurance coverage in India for advanced HCC drugs is patchy. Call us for a written estimate.

Our hepatobiliary doctors

Your case is reviewed by a hepatobiliary surgeon, a medical oncologist with HCC experience, an interventional radiologist trained in TACE and Y-90, a radiation oncologist with SBRT capability, and a hepatologist. Doctor profiles are being added to this site; until then, please call to be matched with the right specialist for your stage and liver function.

Our centers

HealOnco daycare centres run hepatobiliary tumour boards in the Delhi NCR. Our flagship daycare is in Chandigarh, with satellite consultation in Delhi, Gurgaon, Noida, and Faridabad. Find your nearest centre on the city pages below.

Benefits of modern liver cancer techniques vs older approaches

Two decades ago, advanced HCC had one drug, sorafenib, with a modest survival benefit. Today, atezolizumab plus bevacizumab has shown an overall survival improvement over sorafenib in IMbrave150, and the STRIDE doublet from HIMALAYA gives a second first-line immunotherapy option [4]. TACE has moved from gelfoam-and-doxorubicin slurries to drug-eluting beads with predictable pharmacokinetics. Y-90 radioembolisation and SBRT have opened doors for tumours that nothing else could reach. Laparoscopic and robotic liver resections shorten hospital stay and reduce wound problems. The biggest change of all is the multidisciplinary tumour board: HCC is no longer treated by one specialty in isolation.

Is each modality good or bad for you — honest pros and cons

Resection — best chance of cure for a single small HCC in a good liver; recurrence risk remains. Transplant — removes both the cancer and the diseased liver; long wait, donor scarcity, lifelong immunosuppression. Ablation — minimally invasive, short recovery; only for tumours up to about 3 cm and only when reachable. TACE — disease control for intermediate stage; not safe with portal vein thrombosis. Y-90 — works where TACE will not; expensive, not available in every city. SBRT — non-invasive; possible radiation-induced liver injury if liver function is already poor. Atezolizumab + bevacizumab — clear survival benefit; need varices screened first, immune side effects possible. TKIs — oral, accessible; hand-foot syndrome, fatigue, hypertension are common.

Side effects and how we manage them

Surgery carries risks of bleeding, bile leak, and transient liver dysfunction; we mitigate with low CVP anaesthesia, pre-operative optimisation, and a dedicated HPB ICU. TACE causes a post-embolisation syndrome of fever, pain, and nausea in many patients; we manage with antiemetics, IV fluids, and analgesia. Atezolizumab plus bevacizumab can trigger immune colitis, pneumonitis, hepatitis, hypothyroidism, and hypertension; we screen varices first, monitor LFTs and TSH every cycle, and treat immune toxicities with steroids when needed. TKIs cause hand-foot syndrome, diarrhoea, hypertension, and fatigue; dose modification and supportive creams help most patients continue. Cirrhosis complications — ascites, encephalopathy, bleeding varices — need their own active management with diuretics, lactulose, rifaximin, and endoscopic banding.

What our patients say

My father was diagnosed with HCC on a fatty liver. The team explained TACE in plain Hindi, gave us a written cost, and called us the morning after the procedure. We did not feel rushed. — Family member, Chandigarh

I had hepatitis B for years and never knew it could turn into cancer. The surveillance ultrasound caught a 1.8 cm tumour. Ablation, one night in hospital, and I was back at work in a week. — Patient, Mohali

The honest conversation about my mother’s BCLC D stage was hard but it saved her from another round of toxic treatment. The palliative team kept her comfortable at home. — Family member, Delhi

Video testimonials

Video testimonials from our liver cancer patients are being recorded with consent and will be published here as they become available.

Frequently asked questions about liver cancer

Will I need a transplant?

Most patients do not. Transplant is offered when the cancer fits the Milan or expanded criteria and when the rest of the liver is too damaged for resection or ablation.

Can liver cancer be cured?

Yes, in the right situation. Very early and early-stage HCC treated with surgery, ablation, or transplant can be cured in a meaningful share of patients.

Is the surgery very risky?

Modern hepatobiliary surgery in a high-volume unit is much safer than it used to be. Risk depends mostly on how well the rest of the liver works.

Will my hair fall out?

Standard HCC treatments do not usually cause the dramatic hair loss seen with breast or lung cancer chemotherapy. TKIs can cause hair thinning and hand-foot syndrome.

Do I need to stop alcohol completely?

Yes. Alcohol is harmful to a liver that already has cancer or cirrhosis, no matter how small the amount.

I have hepatitis B. Can my family catch it?

Hepatitis B is spread by blood and body fluids, not by sharing food or hugs. Family members should be tested and vaccinated if not already immune.

Should I take herbal liver tonics?

Many herbal products marketed for liver health can actually harm a sick liver. Tell your doctor about everything you take.

Can I work during treatment?

Most patients on oral TKIs or immunotherapy continue to work in some form, with rest days around treatment. Surgery and TACE require recovery weeks.

What about diet?

A protein-rich, salt-light, calorie-adequate diet is the goal for most patients with HCC and cirrhosis.

Will I be in pain?

Pain in liver cancer is treatable. Opioids can be used safely under supervision even in liver disease.

How often will I need scans after treatment?

Every three months for the first two years, then every six months. Surveillance carries on for life.

Can my hepatitis be cured at the same time?

Hepatitis C can now be cured with a short course of direct-acting antivirals. Hepatitis B can be controlled with long-term oral antivirals such as tenofovir or entecavir.

Is immunotherapy safe for me?

Immunotherapy is effective in HCC but is not for everyone. Patients with autoimmune disease, previous organ transplants, or untreated varices need careful screening first.

What if treatment stops working?

Liver cancer care now has several lines of treatment. Moving from a first-line TKI to a second-line TKI or to a checkpoint inhibitor is common.

Medically reviewed by

This page was prepared by the HealOnco hepatobiliary editorial team and medically reviewed on 8 April 2026.

Liver cancer treatment in top cities

• Liver cancer treatment in Delhi
• Gurgaon
• Noida
• Faridabad
• Ghaziabad
• Mumbai
• Bengaluru
• Hyderabad
• Chennai
• Kolkata
• Pune

Liver cancer treatment cost in top cities

• Cost in Delhi
• Gurgaon
• Noida
• Faridabad
• Ghaziabad
• Mumbai
• Bengaluru
• Hyderabad
• Chennai
• Kolkata
• Pune

Related cancers we treat

• Colon cancer
• Rectal cancer
• Prostate cancer

Supportive care

• Pain management
• Nutrition
• Counselling
• Palliative care
• Second opinion

References

1. Globocan 2022, India country profile. IARC. link
2. WHO ICD-11 reference. icd.who.int
3. NCI SEER Liver and Intrahepatic Bile Duct Cancer. seer.cancer.gov
4. NCCN Patient Guidelines, Hepatobiliary Cancers. nccn.org
5. ESMO Patient Guide on Hepatocellular Carcinoma. esmo.org
6. ICMR National Cancer Registry Programme. ncdirindia.org
7. Tata Memorial Centre, hepatobiliary clinic. tmc.gov.in
8. AIIMS New Delhi, hepatobiliary unit. aiims.edu
9. WHO Hepatitis B fact sheet. who.int
10. WHO Hepatitis C fact sheet. who.int
11. IARC Monograph 100F, Aflatoxins. publications.iarc.fr